Tower Research Capital LLC (Trc) Allogene Therapeutics, Inc. Transaction History
Tower Research Capital LLC (Trc)
- $4.87 Billion
- Q4 2024
A detailed history of Tower Research Capital LLC (Trc) transactions in Allogene Therapeutics, Inc. stock. As of the latest transaction made, Tower Research Capital LLC (Trc) holds 9,338 shares of ALLO stock, worth $24,278. This represents 0.0% of its overall portfolio holdings.
Number of Shares
9,338
Previous 5,375
73.73%
Holding current value
$24,278
Previous $15,000
26.67%
% of portfolio
0.0%
Previous 0.0%
Shares
23 transactions
Others Institutions Holding ALLO
# of Institutions
176Shares Held
139MCall Options Held
75.8KPut Options Held
52.8K-
Tpg Gp A, LLC Fort Worth, TX18.7MShares$48.7 Million1.1% of portfolio
-
Black Rock Inc. New York, NY16.4MShares$42.8 Million0.0% of portfolio
-
Lynx1 Capital Management LP San Juan, PR10.9MShares$28.3 Million9.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA8MShares$20.8 Million0.0% of portfolio
-
State Street Corp Boston, MA7.25MShares$18.8 Million0.0% of portfolio
About Allogene Therapeutics, Inc.
- Ticker ALLO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 143,807,008
- Market Cap $374M
- Description
- Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult p...